Cone snails produce a distinctive repertoire of venom peptides that are used both as a defense mechanism and also to facilitate the immobilization and digestion of prey. These peptides target a wide variety of voltage- and ligand-gated ion channels, which make them an invaluable resource for studying the properties of these ion channels in normal and diseased states, as well as being a collection of compounds of potential pharmacological use in their own right. Examples include the United States Food and Drug Administration (FDA) approved pharmaceutical drug, Ziconotide (Prialt ？; Elan Pharmaceuticals, Inc.) that is the synthetic equivalent of the naturally occurring ω-conotoxin MVIIA, whilst several other conotoxins are currently being used as standard research tools and screened as potential therapeutic drugs in pre-clinical or clinical trials. These developments highlight the importance of driving conotoxin-related research. A PubMed query from 1 January 2007 to 31 August 2011 combined with hand-curation of the retrieved articles allowed for the collation of 98 recently identified conotoxins with therapeutic potential which are selectively discussed in this review. Protein sequence similarity analysis tentatively assigned uncharacterized conotoxins to predicted functional classes. Furthermore, conotoxin therapeutic potential for neurodegenerative disorders (NDD) was also inferred.
References
[1]
Olivera, B.M. Conus peptides: Biodiversity-based discovery and exogenomics. J. Biol. Chem. 2006, 281, 31173–31177, doi:10.1074/jbc.R600020200.
Olivera, B.M.; Cruz, L.J.; de Santos, V.; LeCheminant, G.W.; Griffin, D.; Zeikus, R.; McIntosh, J.M.; Galyean, R.; Varga, J.; Gray, W.R.; et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987, 26, 2086–2090, doi:10.1021/bi00382a004. 2441741
[4]
Safo, P.; Rosenbaum, T.; Shcherbatko, A.; Choi, D.Y.; Han, E.; Toledo-Aral, J.J.; Olivera, B.M.; Brehm, P.; Mandel, G. Distinction among neuronal subtypes of voltage-activated sodium channels by mu-conotoxin piiia. J. Neurosci. 2000, 20, 76–80. 10627583
[5]
Catterall, W.A.; Goldin, A.L.; Waxman, S.G. International union of pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 2005, 57, 397–409, doi:10.1124/pr.57.4.4.
[6]
Ichida, S.; Abe, J.; Zhang, Y.A.; Sugihara, K.; Imoto, K.; Wada, T.; Fujita, N.; Sohma, H. Characteristics of the inhibitory effect of calmodulin on specific [125i]omega-conotoxin GVIA binding to crude membranes from chick brain. Neurochem. Res. 2000, 25, 1629–1635, doi:10.1023/A:1026674721542.
[7]
Olivera, B.M.; Miljanich, G.P.; Ramachandran, J.; Adams, M.E. Calcium channel diversity and neurotransmitter release: The omega-conotoxins and omega-agatoxins. Annu. Rev. Biochem. 1994, 63, 823–867, doi:10.1146/annurev.bi.63.070194.004135.
[8]
Sher, E.; Gotti, C.; Canal, N.; Scoppetta, C.; Piccolo, G.; Evoli, A.; Clementi, F. Specificity of calcium channel autoantibodies in lambert-eaton myasthenic syndrome. Lancet 1989, 2, 640–643. 2570899
[9]
Bowersox, S.S.; Luther, R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon 1998, 36, 1651–1658, doi:10.1016/S0041-0101(98)00158-5.
[10]
Barton, M.E.; White, H.S.; Wilcox, K.S. The effect of CGX-1007 and CI-1041, novel nmda receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res. 2004, 59, 13–24, doi:10.1016/j.eplepsyres.2003.12.011.
[11]
Craig, A.G.; Norberg, T.; Griffin, D.; Hoeger, C.; Akhtar, M.; Schmidt, K.; Low, W.; Dykert, J.; Richelson, E.; Navarro, V.; et al. Contulakin-G, an O-glycosylated invertebrate neurotensin. J. Biol. Chem. 1999, 274, 13752–13759, doi:10.1074/jbc.274.20.13752. 10318778
[12]
Kern, S.E.; Allen, J.; Wagstaff, J.; Shafer, S.L.; Yaksh, T. The pharmacokinetics of the conopeptide contulakin-G (CGX-1160) after intrathecal administration: An analysis of data from studies in beagles. Anesth. Analg. 2007, 104, 1514–1520, doi:10.1213/01.ane.0000262038.58546.e6.
[13]
Lubbers, N.L.; Campbell, T.J.; Polakowski, J.S.; Bulaj, G.; Layer, R.T.; Moore, J.; Gross, G.J.; Cox, B.F. Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. 2005, 46, 141–146, doi:10.1097/01.fjc.0000167015.84715.27.
[14]
Livett, B.G.; Sandall, D.W.; Keays, D.; Down, J.; Gayler, K.R.; Satkunanathan, N.; Khalil, Z. Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon 2006, 48, 810–829, doi:10.1016/j.toxicon.2006.07.023.
[15]
Nielsen, C.K.; Lewis, R.J.; Alewood, D.; Drinkwater, R.; Palant, E.; Patterson, M.; Yaksh, T.L.; McCumber, D.; Smith, M.T. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005, 118, 112–124, doi:10.1016/j.pain.2005.08.002.
[16]
Obata, H.; Conklin, D.; Eisenach, J.C. Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain 2005, 113, 271–276, doi:10.1016/j.pain.2004.10.017.
[17]
Yan, L.D.; Liu, Y.L.; Zhang, L.; Dong, H.J.; Zhou, P.L.; Su, R.B.; Gong, Z.H.; Huang, P.T. Spinal antinociception of synthetic omega-conotoxin SO-3, a selective N-type neuronal voltage-sensitive calcium channel blocker, and its effects on morphine analgesia in chemical stimulus tests in rodent. Eur. J. Pharmacol. 2010, 636, 73–81, doi:10.1016/j.ejphar.2010.03.036.
[18]
Gasior, M.; White, N.A.; Rogawski, M.A. Prolonged attenuation of amygdala-kindled seizure measures in rats by convection-enhanced delivery of the N-type calcium channel antagonists omega-conotoxin GVIA and omega-conotoxin MVIIA. J. Pharmacol. Exp. Ther. 2007, 323, 458–468, doi:10.1124/jpet.107.125047.
[19]
Shahlaie, K.; Lyeth, B.G.; Gurkoff, G.G.; Muizelaar, J.P.; Berman, R.F. Neuroprotective effects of selective N-type VGCC blockade on stretch-injury-induced calcium dynamics in cortical neurons. J. Neurotrauma 2010, 27, 175–187, doi:10.1089/neu.2009.1003.
[20]
Chen, P.; Dendorfer, A.; Finol-Urdaneta, R.K.; Terlau, H.; Olivera, B.M. Biochemical characterization of kappam-RIIIJ, a Kv1.2 channel blocker: Evaluation of cardioprotective effects of kappam-conotoxins. J. Biol. Chem. 2010, 285, 14882–14889, doi:10.1074/jbc.M109.068486. 20220134
[21]
Lahiry, A.; Dave, K. Conotoxins: Review and docking studies to determine potentials of conotoxin as an anticancer drug molecule. Curr. Top. Med. Chem. 2012. in press.
[22]
Waxman, S.G. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat. Rev. Neurosci. 2006, 7, 932–941, doi:10.1038/nrn2023.
[23]
Haydar, S.N.; Dunlop, J. Neuronal nicotinic acetylcholine receptors—Targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer’s disease. Curr. Top. Med. Chem. 2010, 10, 144–152, doi:10.2174/156802610790410983.
[24]
Sayers, E.W.; Barrett, T.; Benson, D.A.; Bolton, E.; Bryant, S.H.; Canese, K.; Chetvernin, V.; Church, D.M.; Dicuccio, M.; Federhen, S.; et al. Database resources of the national center for biotechnology information. Nucleic Acids Res. 2010, 38, D5–D16, doi:10.1093/nar/gkp967. 19910364
[25]
French, R.J.; Terlau, H. Sodium channel toxins—Receptor targeting and therapeutic potential. Curr. Med. Chem. 2004, 11, 3053–3064, doi:10.2174/0929867043363866. 15578999
[26]
Wood, J.N.; Boorman, J.P.; Okuse, K.; Baker, M.D. Voltage-gated sodium channels and pain pathways. J. Neurobiol. 2004, 61, 55–71, doi:10.1002/neu.20094.
Xu, R.; Thomas, E.A.; Jenkins, M.; Gazina, E.V.; Chiu, C.; Heron, S.E.; Mulley, J.C.; Scheffer, I.E.; Berkovic, S.F.; Petrou, S. A childhood epilepsy mutation reveals a role for developmentally regulated splicing of a sodium channel. Mol. Cell. Neurosci. 2007, 35, 292–301, doi:10.1016/j.mcn.2007.03.003.
[29]
Catterall, W.A.; Kalume, F.; Oakley, J.C. Nav1.1 channels and epilepsy. J. Physiol. 2010, 588, 1849–1859, doi:10.1113/jphysiol.2010.187484.
[30]
Gutman, G.A.; Chandy, K.G.; Grissmer, S.; Lazdunski, M.; McKinnon, D.; Pardo, L.A.; Robertson, G.A.; Rudy, B.; Sanguinetti, M.C.; Stuhmer, W.; et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 2005, 57, 473–508, doi:10.1124/pr.57.4.10.
[31]
Mani, B.K.; Brueggemann, L.I.; Cribbs, L.L.; Byron, K.L. Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery. Br. J. Pharmacol. 2011, 164, 237–249, doi:10.1111/j.1476-5381.2011.01273.x.
[32]
Takeda, M.; Tanimoto, T.; Nasu, M.; Matsumoto, S. Temporomandibular joint inflammation decreases the voltage-gated K+ channel subtype 1.4-immunoreactivity of trigeminal ganglion neurons in rats. Eur. J. Pain 2008, 12, 189–195, doi:10.1016/j.ejpain.2007.04.005.
[33]
Martel, P.; Leo, D.; Fulton, S.; Berard, M.; Trudeau, L.E. Role of Kv1 potassium channels in regulating dopamine release and presynaptic D2 receptor function. PLoS One 2011, 6.
[34]
Cahalan, M.D.; Chandy, K.G. Ion channels in the immune system as targets for immunosuppression. Curr. Opin. Biotechnol. 1997, 8, 749–756, doi:10.1016/S0958-1669(97)80130-9.
Ellison, D.H. The voltage-gated K+ channel subunit Kv1.1 links kidney and brain. J. Clin. Invest. 2009, 119, 763–766, doi:10.1172/JCI38835.
[38]
Su, X.; Leon, L.A.; Laping, N.J. Role of spinal Cav2.2 and Cav2.1 ion channels in bladder nociception. J. Urol. 2008, 179, 2464–2469, doi:10.1016/j.juro.2008.01.088.
[39]
Ilijic, E.; Guzman, J.N.; Surmeier, D.J. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol. Dis. 2011, 43, 364–371, doi:10.1016/j.nbd.2011.04.007.
[40]
Wildburger, N.C.; Lin-Ye, A.; Baird, M.A.; Lei, D.; Bao, J. Neuroprotective effects of blockers for T-type calcium channels. Mol. Neurodegener. 2009, 4.
Liu, J.; Wu, Q.; Pi, C.; Zhao, Y.; Zhou, M.; Wang, L.; Chen, S.; Xu, A. Isolation and characterization of a T-superfamily conotoxin from Conus litteratus with targeting tetrodotoxin-sensitive sodium channels. Peptides 2007, 28, 2313–2319, doi:10.1016/j.peptides.2007.09.006.
[43]
Wang, L.; Pi, C.; Liu, J.; Chen, S.; Peng, C.; Sun, D.; Zhou, M.; Xiang, H.; Ren, Z.; Xu, A. Identification and characterization of a novel O-superfamily conotoxin from Conus litteratus. J. Pept. Sci. 2008, 14, 1077–1083, doi:10.1002/psc.1044.
[44]
Lewis, R.J.; Schroeder, C.I.; Ekberg, J.; Nielsen, K.J.; Loughnan, M.; Thomas, L.; Adams, D.A.; Drinkwater, R.; Adams, D.J.; Alewood, P.F. Isolation and structure-activity of mu-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. Mol. Pharmacol. 2007, 71, 676–685. 17142296
[45]
Gilly, W.F.; Richmond, T.A.; Duda, T.F., Jr.; Elliger, C.; Lebaric, Z.; Schulz, J.; Bingham, J.P.; Sweedler, J.V. A diverse family of novel peptide toxins from an unusual cone snail, Conus californicus. J. Exp. Biol. 2011, 214, 147–161, doi:10.1242/jeb.046086. 21147978
[46]
Holford, M.; Zhang, M.M.; Gowd, K.H.; Azam, L.; Green, B.R.; Watkins, M.; Ownby, J.P.; Yoshikami, D.; Bulaj, G.; Olivera, B.M. Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus. Toxicon 2009, 53, 90–98, doi:10.1016/j.toxicon.2008.10.017.
[47]
Schroeder, C.I.; Ekberg, J.; Nielsen, K.J.; Adams, D.; Loughnan, M.L.; Thomas, L.; Adams, D.J.; Alewood, P.F.; Lewis, R.J. Neuronally micro-conotoxins from Conus striatus utilize an alpha-helical motif to target mammalian sodium channels. J. Biol. Chem. 2008, 283, 21621–21628, doi:10.1074/jbc.M802852200. 18522941
[48]
Lee, S.; Kim, Y.; Back, S.K.; Choi, H.W.; Lee, J.Y.; Jung, H.H.; Ryu, J.H.; Suh, H.W.; Na, H.S.; Kim, H.J.; et al. Analgesic effect of highly reversible omega-conotoxin fvia on N type Ca2+ channels. Mol. Pain 2010, 6.
[49]
Bernaldez, J.; Lopez, O.; Licea, A.; Salceda, E.; Arellano, R.O.; Vega, R.; Soto, E. Electrophysiological characterization of a novel small peptide from the venom of Conus californicus that targets voltage-gated neuronal Ca2+ channels. Toxicon 2011, 57, 60–67, doi:10.1016/j.toxicon.2010.09.015.
[50]
Aguilar, M.B.; Lopez-Vera, E.; de la Cotera, E.P.H.; Falcon, A.; Olivera, B.M.; Maillo, M. I-conotoxins in vermivorous species of the west atlantic: Peptide sr11a from Conus spurius. Peptides 2007, 28, 18–23, doi:10.1016/j.peptides.2006.08.024.
[51]
Aguilar, M.B.; Perez-Reyes, L.I.; Lopez, Z.; de la Cotera, E.P.H.; Falcon, A.; Ayala, C.; Galvan, M.; Salvador, C.; Escobar, L.I. Peptide sr11a from Conus spurius is a novel peptide blocker for Kv1 potassium channels. Peptides 2010, 31, 1287–1291, doi:10.1016/j.peptides.2010.04.007.
[52]
Quik, M.; Wonnacott, S. α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson’s disease. Pharmacol. Rev. 2011, 63, 938–966, doi:10.1124/pr.110.003269.
[53]
Tong, M.; Arora, K.; White, M.M.; Nichols, R.A. Role of key aromatic residues in the ligand-binding domain of α7 nicotinic receptors in the agonist action of β-amyloid. J. Biol. Chem. 2011, 286, 34373–34381, doi:10.1074/jbc.M111.241299. 21828053
[54]
Marquis, K.L.; Comery, T.A.; Jow, F.; Navarra, R.L.; Grauer, S.M.; Pulicicchio, C.; Kelley, C.; Brennan, J.A.; Roncarati, R.; Scali, C.; et al. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology (Berl.) 2011, 218, 635–647, doi:10.1007/s00213-011-2357-6.
[55]
Raffa, R.B. Cancer “survivor-care”: I. The alpha7 nachr as potential target for chemotherapy-related cognitive impairment. J. Clin. Pharm. Ther. 2010, 36, 437–445, doi:10.1111/j.1365-2710.2010.01208.x.
[56]
Vincler, M.; Wittenauer, S.; Parker, R.; Ellison, M.; Olivera, B.M.; McIntosh, J.M. Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors. Proc. Natl. Acad. Sci. USA 2006, 103, 17880–17884, doi:10.1073/pnas.0608715103. 17101979
[57]
Kauferstein, S.; Kendel, Y.; Nicke, A.; Coronas, F.I.; Possani, L.D.; Favreau, P.; Krizaj, I.; Wunder, C.; Kauert, G.; Mebs, D. New conopeptides of the D-superfamily selectively inhibiting neuronal nicotinic acetylcholine receptors. Toxicon 2009, 54, 295–301, doi:10.1016/j.toxicon.2009.04.016.
[58]
Loughnan, M.; Nicke, A.; Jones, A.; Schroeder, C.I.; Nevin, S.T.; Adams, D.J.; Alewood, P.F.; Lewis, R.J. Identification of a novel class of nicotinic receptor antagonists: Dimeric conotoxins VxXIIA, VxXIIB, and VxXIIC from Conus vexillu. J. Biol. Chem. 2006, 281, 24745–24755, doi:10.1074/jbc.M603703200. 16790424
[59]
Jimenez, E.C.; Olivera, B.M.; Teichert, R.W. Alphac-conotoxin PrXA: A new family of nicotinic acetylcholine receptor antagonists. Biochemistry 2007, 46, 8717–8724, doi:10.1021/bi700582m.
[60]
Lluisma, A.O.; Lopez-Vera, E.; Bulaj, G.; Watkins, M.; Olivera, B.M. Characterization of a novel psi-conotoxin from Conus parius reeve. Toxicon 2008, 51, 174–180, doi:10.1016/j.toxicon.2007.07.009.
[61]
Shon, K.J.; Grilley, M.; Jacobsen, R.; Cartier, G.E.; Hopkins, C.; Gray, W.R.; Watkins, M.; Hillyard, D.R.; Rivier, J.; Torres, J.; et al. A noncompetitive peptide inhibitor of the nicotinic acetylcholine receptor from Conus purpurascens venom. Biochemistry 1997, 36, 9581–9587, doi:10.1021/bi970235w. 9236004
[62]
Peng, C.; Ye, M.; Wang, Y.; Shao, X.; Yuan, D.; Liu, J.; Hawrot, E.; Wang, C.; Chi, C. A new subfamily of conotoxins belonging to the A-superfamily. Peptides 2010, 31, 2009–2016, doi:10.1016/j.peptides.2010.07.011. 20691232
[63]
Lopez-Vera, E.; Jacobsen, R.B.; Ellison, M.; Olivera, B.M.; Teichert, R.W. A novel alpha conotoxin (alpha-PIB) isolated from C. purpurascens is selective for skeletal muscle nicotinic acetylcholine receptors. Toxicon 2007, 49, 1193–1199, doi:10.1016/j.toxicon.2007.02.007.
[64]
Lopez-Vera, E.; Aguilar, M.B.; Schiavon, E.; Marinzi, C.; Ortiz, E.; Restano Cassulini, R.; Batista, C.V.; Possani, L.D.; de la Cotera, E.P.H.; Peri, F.; et al. Novel alpha-conotoxins from Conus spurius and the alpha-conotoxin ei share high-affinity potentiation and low-affinity inhibition of nicotinic acetylcholine receptors. FEBS J. 2007, 274, 3972–3985, doi:10.1111/j.1742-4658.2007.05931.x. 17635581
[65]
Park, K.H.; Suk, J.E.; Jacobsen, R.; Gray, W.R.; McIntosh, J.M.; Han, K.H. Solution conformation of alpha-conotoxin EI, a neuromuscular toxin specific for the alpha 1/delta subunit interface of torpedo nicotinic acetylcholine receptor. J. Biol. Chem. 2001, 276, 49028–49033, doi:10.1074/jbc.M107798200. 11641403
[66]
Yuan, D.D.; Han, Y.H.; Wang, C.G.; Chi, C.W. From the identification of gene organization of alpha conotoxins to the cloning of novel toxins. Toxicon 2007, 49, 1135–1149, doi:10.1016/j.toxicon.2007.02.011.
[67]
Liu, L.; Chew, G.; Hawrot, E.; Chi, C.; Wang, C. Two potent alpha3/5 conotoxins from piscivorous Conus achatinus. Acta Biochim. Biophys. Sin. (Shanghai) 2007, 39, 438–444, doi:10.1111/j.1745-7270.2007.00301.x.
[68]
Whiteaker, P.; Christensen, S.; Yoshikami, D.; Dowell, C.; Watkins, M.; Gulyas, J.; Rivier, J.; Olivera, B.M.; McIntosh, J.M. Discovery, synthesis, and structure activity of a highly selective alpha7 nicotinic acetylcholine receptor antagonist. Biochemistry 2007, 46, 6628–6638, doi:10.1021/bi7004202. 17497892
[69]
Dutertre, S.; Ulens, C.; Buttner, R.; Fish, A.; van Elk, R.; Kendel, Y.; Hopping, G.; Alewood, P.F.; Schroeder, C.; Nicke, A.; et al. Achbp-targeted alpha-conotoxin correlates distinct binding orientations with nachr subtype selectivity. EMBO J. 2007, 26, 3858–3867, doi:10.1038/sj.emboj.7601785.
[70]
Johnson, M.; Zaretskaya, I.; Raytselis, Y.; Merezhuk, Y.; McGinnis, S.; Madden, T.L. NCBI BLAST: A better web interface. Nucleic Acids Res. 2008, 36, W5–W9, doi:10.1093/nar/gkn201.
[71]
Larkin, M.A.; Blackshields, G.; Brown, N.P.; Chenna, R.; McGettigan, P.A.; McWilliam, H.; Valentin, F.; Wallace, I.M.; Wilm, A.; Lopez, R.; et al. Clustal W and clustal X version 2.0. Bioinformatics 2007, 23, 2947–2948, doi:10.1093/bioinformatics/btm404. 17846036
[72]
Ramoz, N.; Boni, C.; Downing, A.M.; Close, S.L.; Peters, S.L.; Prokop, A.M.; Allen, A.J.; Hamon, M.; Purper-Ouakil, D.; Gorwood, P. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 2009, 34, 2135–2142, doi:10.1038/npp.2009.39.
[73]
Brust, A.; Palant, E.; Croker, D.E.; Colless, B.; Drinkwater, R.; Patterson, B.; Schroeder, C.I.; Wilson, D.; Nielsen, C.K.; Smith, M.T.; et al. chi-Conopeptide pharmacophore development: Toward a novel class of norepinephrine transporter inhibitor (Xen2174) for pain. J. Med. Chem. 2009, 52, 6991–7002, doi:10.1021/jm9003413. 19860431
[74]
Kits, K.S.; Lodder, J.C.; van der Schors, R.C.; Li, K.W.; Geraerts, W.P.; Fainzilber, M. Novel omega-conotoxins block dihydropyridine-insensitive high voltage-activated calcium channels in molluscan neurons. J. Neurochem. 1996, 67, 2155–2163. 8863526
[75]
Kuo, I.Y.; Ellis, A.; Seymour, V.A.; Sandow, S.L.; Hill, C.E. Dihydropyridine-insensitive calcium currents contribute to function of small cerebral arteries. J. Cereb. Blood Flow Metab. 2010, 30, 1226–1239, doi:10.1038/jcbfm.2010.11.
Mousavi, M.; Hellstrom-Lindahl, E.; Guan, Z.Z.; Shan, K.R.; Ravid, R.; Nordberg, A. Protein and mrna levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer’s disease. Neuroscience 2003, 122, 515–520, doi:10.1016/S0306-4522(03)00460-3.
Srivareerat, M.; Tran, T.T.; Salim, S.; Aleisa, A.M.; Alkadhi, K.A. Chronic nicotine restores normal abeta levels and prevents short-term memory and e-ltp impairment in abeta rat model of Alzheimer’s disease. Neurobiol. Aging 2011, 32, 834–844, doi:10.1016/j.neurobiolaging.2009.04.015.
[80]
Mousavi, M.; Hellstrom-Lindahl, E. Nicotinic receptor agonists and antagonists increase sappalpha secretion and decrease abeta levels in vitro. Neurochem. Int. 2009, 54, 237–244, doi:10.1016/j.neuint.2008.12.001.
[81]
Kim, S.; Rhim, H. Effects of amyloid-beta peptides on voltage-gated l-type Cav1.2 and Cav1.3 Ca2+ channels. Mol. Cells 2011, 32, 289–294, doi:10.1007/s10059-011-0075-x.
[82]
Anekonda, T.S.; Quinn, J.F. Calcium channel blocking as a therapeutic strategy for Alzheimer’s disease: The case for isradipine. Biochim. Biophys. Acta 2011, 1812, 1584–1590, doi:10.1016/j.bbadis.2011.08.013. 21925266
[83]
Ye, H.; Jalini, S.; Mylvaganam, S.; Carlen, P. Activation of large-conductance Ca2+-activated K+ channels depresses basal synaptic transmission in the hippocampal CA1 area in APP (swe/ind) TgCRND8 mice. Neurobiol. Aging 2010, 31, 591–604, doi:10.1016/j.neurobiolaging.2008.05.012.
[84]
Meyer, A.K.; Maisel, M.; Hermann, A.; Stirl, K.; Storch, A. Restorative approaches in Parkinson’s disease: Which cell type wins the race? J. Neurol. Sci. 2010, 289, 93–103, doi:10.1016/j.jns.2009.08.024.
[85]
Perez, X.A.; Bordia, T.; McIntosh, J.M.; Quik, M. Alpha6ss2* and alpha4ss2* nicotinic receptors both regulate dopamine signaling with increased nigrostriatal damage: Relevance to Parkinson’s disease. Mol. Pharmacol. 2010, 78, 971–980, doi:10.1124/mol.110.067561.
[86]
Kawamata, J.; Shimohama, S. Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer’s and Parkinson’s diseases. J. Alzheimers Dis. 2011, 24, 95–109. 21403387
[87]
Tai, C.H.; Yang, Y.C.; Pan, M.K.; Huang, C.S.; Kuo, C.C. Modulation of subthalamic T-type Ca2+ channels remedies locomotor deficits in a rat model of Parkinson disease. J. Clin. Invest. 2011, 121, 3289–3305, doi:10.1172/JCI46482.
[88]
Liu, X.K.; Wang, G.; Chen, S.D. Modulation of the activity of dopaminergic neurons by SK channels: A potential target for the treatment of Parkinson’s disease? Neurosci. Bull. 2010, 26, 265–271, doi:10.1007/s12264-010-1217-4.
Craner, M.J.; Newcombe, J.; Black, J.A.; Hartle, C.; Cuzner, M.L.; Waxman, S.G. Molecular changes in neurons in multiple sclerosis: Altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc. Natl. Acad. Sci. USA 2004, 101, 8168–8173, doi:10.1073/pnas.0402765101. 15148385
[91]
Craner, M.J.; Damarjian, T.G.; Liu, S.; Hains, B.C.; Lo, A.C.; Black, J.A.; Newcombe, J.; Cuzner, M.L.; Waxman, S.G. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005, 49, 220–229, doi:10.1002/glia.20112.
[92]
Brand-Schieber, E.; Werner, P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp. Neurol. 2004, 189, 5–9, doi:10.1016/j.expneurol.2004.05.023.
[93]
Wulff, H.; Calabresi, P.A.; Allie, R.; Yun, S.; Pennington, M.; Beeton, C.; Chandy, K.G. The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111, 1703–1713. 12782673
[94]
Shimohama, S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull. 2009, 32, 332–336, doi:10.1248/bpb.32.332. 19252273
